(19)
(11) EP 3 217 979 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
03.06.2020 Bulletin 2020/23

(45) Mention of the grant of the patent:
08.04.2020 Bulletin 2020/15

(21) Application number: 15708275.1

(22) Date of filing: 20.01.2015
(51) International Patent Classification (IPC): 
A61K 31/439(2006.01)
 A61P 31/00(2006.01)
(86) International application number:
PCT/IB2015/050421
(87) International publication number:
WO 2015/110950 (30.07.2015 Gazette 2015/30)

(54)

PHARMACEUTICAL COMPOSITIONS COMPRISING ANTIBACTERIAL AGENTS

PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT ANTIBAKTERIELLEN WIRKSTOFFEN

COMPOSITIONS PHARMACEUTIQUES COMPRENANT DES AGENTS ANTIBACTÉRIENS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 21.01.2014 IN 193MU2014

(43) Date of publication of application:
20.09.2017 Bulletin 2017/38

(73) Proprietor: Wockhardt Bio AG
6300 Zug (CH)

(72) Inventors:
  • PATEL, Mahesh Vithalbhai
    Mararashtra Aurangabad 431003 (IN)
  • BHAGWAT, Sachin
    Aurangabad 431005 (IN)
  • SATAV, Jaykumar Satwaji
    Hingoli 431702 (IN)
  • KHANDE, Hemant Narendra
    Nashik 422215 (IN)
  • JOSHI, Prashant Ratnakar
    Parbhani 431401 (IN)
  • PALWE, Snehal Rameshwar
    Buldhana 443001 (IN)

(74) Representative: Nederlandsch Octrooibureau 
P.O. Box 29720
2502 LS The Hague
2502 LS The Hague (NL)


(56) References cited: : 
WO-A1-2013/030733
CA-A1- 2 874 279
 WO-A1-2014/108872
US-A1- 2013 225 554
   
     
    Remarks:
    The file contains technical information submitted after the application was filed and not included in this specification
     
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).